Loading company…
Yinzhu Pharma develops antitumor drugs, including a treatment for advanced non-small cell lung cancer.
Founded in 2016 and based in Guangzhou, China, Yinzhu Pharma develops antitumor drugs and has applied for and received authorization for thirty-five domestic and foreign invention patents. Its carboxylaminotriazole soft capsule is a non-cytotoxic drug targeting TNF-a for advanced non-small cell lung cancer. In September 2020, the company raised CNY 45 million in Series A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in